FDA advisory committees
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription Drugs Advisory Committee slated to meet March 6-7, June 13-14 and Sept. 16-17, according to 1tentative 2003 advisory committee schedule published in Dec. 19 Federal Register. NDAC considered Rx-to-OTC switch applications for Schering-Plough's Claritin (loratadine) and AstraZeneca/Procter & Gamble's Prilosec (omeprazole), and discussed labeling and marketing for acetaminophen, aspirin and NSAIDs in 2002. CFSAN's Dietary Supplements Subcommittee of the Food Advisory Committee is slated to meet March 27-28 and Sept. 22-23, while the parent committee is scheduled to convene Feb. 24-26 and Aug. 18-20...
You may also be interested in...
NDAC meetings rescheduled
Nonprescription Drugs Advisory Committee tentative meeting dates have been rescheduled for June 12-13 and Sept. 16-17. Dietary Supplements Subcommittee tentative meeting dates still slated for March 27-28 and Sept. 22-23, as reported in 1"The Tan Sheet" Dec. 23, 2002, In Brief...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.